# Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

> **NCT00303524** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 170 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Goserelin acetate
- **DRUG:** Goserelin acetate

## Key facts

- **NCT ID:** NCT00303524
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-08
- **Final completion:** 2009-02
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303524, "Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00303524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*